DB17413ExperimentalProtein Based Therapies
A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (trastuzumab) via a stable protease-cleavable valine citrulline linker.
- Mechanism
- Curator reviewed
Pharmacologically active on Receptor tyrosine-protein kinase erbB-2
- Code names
- A-166
Resolves to
Compound
Targets
What you can answer from here — as of June 15, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Trastuzumab botidotin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account